Mechanisms of Drug Resistance Related to the Microenvironment of Solid Tumors and Possible Strategies to Inhibit Them

Cancer Journal (United States)

Volumn 21, Issue 4, 2015, Pages 254-262

  Tan, Qian ^a   Saggar, Jasdeep K ^a   Yu, Man ^a   Wang, Marina ^a   Tannock, Ian F ^a,b,c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Autophagy; chemotherapy; drug distribution; drug resistance; hypoxia

Indexed keywords

ANTINEOPLASTIC AGENT; PRODRUG;

ACIDITY; AUTOPHAGY; BLOOD VESSEL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL ORGANELLE; DRUG DISTRIBUTION; DRUG EFFECT; HUMAN; HYPOXIA; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TREATMENT OUTCOME; TUMOR CELL; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; ANOXIA; DRUG RESISTANCE; METABOLISM; NEOPLASMS; PH; VASCULARIZATION;

ANOXIA; ANTINEOPLASTIC AGENTS; AUTOPHAGY; DRUG RESISTANCE, NEOPLASM; HUMANS; HYDROGEN-ION CONCENTRATION; NEOPLASMS; PRODRUGS; TUMOR MICROENVIRONMENT;

EID: 84938577774     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0000000000000131     Document Type: Review

References (74)

1. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer. 2006;6:583-592.
2. TredanO, Galmarini CM, PatelK, et al. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst. 2007;99:1441-1454.
3. Lankelma J, Dekker H, Luque FR, et al. Doxorubicin gradients in human breast cancer. Clin Cancer Res. 1999;5:1703-1707.
4. Huxham LA, Kyle AH, Baker JH, et al. Microregional effects of gemcitabine in HCT-116 xenografts. Cancer Res. 2004;64:6537-6541.
5. Hirst DG, Denekamp J. Tumour cell proliferation in relation to the vasculature. Cell Tissue Kinet. 1979;12:31-42.
6. Ljungkvist AS, Bussink J, Rijken PF, et al. Vascular architecture, hypoxia, and proliferation in first-generation xenografts of human head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys. 2002;54: 215-228.
7. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol. 2004;14:198-206.
8. Vaupel P, Harrison L. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist. 2004;9(suppl 5):4-9.
9. Chaplin DJ, Trotter MJ, Durand RE, et al. Evidence for intermittent radiobiological hypoxia in experimental tumour systems. Biomed Biochim Acta. 1989;48:S255-S259.
10. Durand RE, LePard NE. Contribution of transient blood flow to tumour hypoxia in mice. Acta Oncol. 1995;34:317-323.
11. Graeber TG, Osmanian C, Jacks T, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 1996; 379:88-91.
12. HaensgenG,KrauseU, BeckerA, et al. Tumor hypoxia, p53, and prognosis in cervical cancers. Int J Radiat Oncol Biol Phys. 2001;50:865-872.
13. Ogiso Y, Tomida A, Lei S, et al. Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs. Cancer Res. 2000; 60:2429-2434.
14. WartenbergM, Ling FC, MüschenM, et al. Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species. FASEB J. 2003;17:503-505
15. Azad MB, Chen Y, Henson ES, et al. Hypoxia induces autophagic cell death in apoptosis-competent cells through a mechanism involving BNIP3. Autophagy. 2008;4:195-204.
16. Rouschop KM, van den Beucken T, Dubois L, et al. The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5. J Clin Invest. 2010;120: 127-141.
17. Warburg O. On the origin of cancer cells. Science. 1956;123:309-314.
18. Tannock IF, Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. 1989;49:4373-4384.
19. Svastova E, Hulíková A, Rafajová M, et al. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett. 2004;577:439-445.
20. Huang Z, Huang Y. The change of intracellular pH is involved in the cisplatin-resistance of human lung adenocarcinoma A549/DDP cells. Cancer Invest. 2005;23:26-32.
21. Patel KJ, Trédan O, Tannock IF. Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues. Cancer Chemother Phamacol. in press;72:127-138.
22. Lee CM, Tannock IF. Inhibition of endosomal sequestration of basic anticancer drugs: influence on cytotoxicity and tissue penetration. Br J Cancer. 2006;94:863-869.
23. Luciani F, SpadaM,DeMilitoA, et al. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst. 2004;96:1702-1713.
24. De Milito A, Iessi E, Logozzi M, et al. Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species. Cancer Res. 2007;67: 5408-5417.
25. MarinoML, Fais S, Djavaheri-Mergny M, et al. Proton pump inhibition induces autophagy as a survival mechanism following oxidative stress in human melanoma cells. Cell Death Dis. 2010;1:e87.
26. Patel KJ, Lee C, TanQ, et al. Use of the proton pump inhibitor pantoprazole to modify the distribution and activity of doxorubicin: a potential strategy to improve the therapy of solid tumors. Clin Cancer Res. 2013;19: 6766-6776.
27. Tan Q, Joshua AM, Saggar JK, et al. Effect of pantoprazole to enhance activity of docetaxel against human tumour xenografts by inhibiting autophagy. Br J Cancer. 2015;112:832-840.
28. Hoyer-Hansen M, Jaattela M. Connecting endoplasmic reticulum stress to autophagy by unfolded protein response and calcium. Cell Death Differ. 2007;14:1576-1582.
29. Mizushima N, Ohsumi Y, Yoshimori T. Autophagosome formation in mammalian cells. Cell Struct Funct. 2002;27:421-429.
30. Gozuacik D, Kimchi A. Autophagy as a cell death and tumor suppressor mechanism. Oncogene. 2004;23:2891-2906.
31. Ganley IG, Wong PM, Gammoh N, et al. Distinct autophagosomallysosomal fusion mechanism revealed by thapsigargin-induced autophagy arrest. Mol Cell. 2011;42:731-743.
32. Tsukada M, Ohsumi Y. Isolation and characterization of autophagydefective mutants of Saccharomyces cerevisiae. FEBS Lett. 1993;333: 169-174.
33. Tanida I,Ueno T, Kominami E. LC3 conjugation systeminmammalian autophagy. Int J Biochem Cell Biol. 2004;36:2503-2518.
34. Klionsky DJ, Abdalla FC, Abeliovich H, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2012;8: 445-544.
35. Bjorkoy G, Lamark T, Pankiv S, et al. Monitoring autophagic degradation of p62/SQSTM1. Methods Enzymol. 2009;452:181-197.
36. Li J, Hou N, Faried A, et al. Inhibition of autophagy by 3-MAenhances the effect of 5-FU-induced apoptosis in colon cancer cells. Ann Surg Oncol. 2009;16:761-771.
37. Karpathiou G, Sivridis E, Koukourakis MI, et al. Light-chain 3A autophagic activity and prognostic significance in non-small cell lung carcinomas. Chest. 2011;140:127-134.
38. Sivridis E, Koukourakis MI, Mendrinos SE, et al. Beclin-1 and LC3A expression in cutaneous malignant melanomas: a biphasic survival pattern for beclin-1. Melanoma Res. 2011;21:188-195.
39. Sharma N, Thomas S, Golden EB, et al. Inhibition of autophagy and induction of breast cancer cell death by mefloquine, an antimalarial agent. Cancer Lett. 2012;326:143-154.
40. Yang ZJ, Chee CE, Huang S, et al. The role of autophagy in cancer: therapeutic implications. Mol Cancer Ther. 2011;10:1533-1541.
41. Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res. 1988;48(24 pt 1):7022-7032.
42. Jain RK. Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J Natl Cancer Inst. 1989;81:570-576.
43. Undevia SD, Gomez-Abuin G, Ratain MJ. Pharmacokinetic variability of anticancer agents. Nat Rev Cancer. 2005;5:447-458.
44. Conger AD, Ziskin MC. Growth of mammalian multicellular tumor spheroids. Cancer Res. 1983;43:556-560.
45. Sutherland RM. Cell and environment interactions in tumor microregions: the multicell spheroid model. Science. 1988;240:177-184.
46. Tannock IF, Lee CM, Tunggal JK, et al. Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res. 2002;8:878-884.
47. Hicks KO, Pruijn FB, Secomb TW, et al. Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxiatargeted anticancer drugs. J Natl Cancer Inst. 2006;98:1118-1128.
48. Durand RE. Distribution and activity of antineoplastic drugs in a tumor model. J Natl Cancer Inst. 1989;81:146-152.
49. Lesser GJ, Grossman SA, Eller S, et al. The distribution of systemically administered [3H]-paclitaxel in rats: a quantitative autoradiographic study. Cancer Chemother Pharmacol. 1995;37:73-78.
50. Kuh HJ, Jang SH, Wientjes MG, et al. Determinants of paclitaxel penetration and accumulation in human solid tumor. J Pharmacol Exp Ther. 1999; 290:871-880.
51. WilsonWR, HayMP. Targeting hypoxia in cancer therapy. Nat Rev Cancer. 2011;11:393-410.
52. Choi MS, Kim SH, Kuh HJ. Penetration of paclitaxel and 5-fluorouracil in multicellular layers of human colorectal cancer cells. Oncol Rep. 2011;25: 863-870.
53. Yuan F, Salehi HA, Boucher Y, et al. Vascular permeability andmicrocirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. Cancer Res. 1994;54:4564-4568.
54. Helmlinger G, Yuan F, Dellian M, et al. Interstitial pH and PO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med. 1997;3:177-182.
55. Brana I, Ocana A, Chen EX, et al. A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin. Invest New Drugs. 2014;32:1269-1277.
56. Primeau AJ, Rendon A, Hedley D, et al. The distribution of the anticancer drug doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res. 2005;11:8782-8788.
57. Patel KJ, Tredan O, Tannock IF. Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues. Cancer Chemother Pharmacol. 2013;72:127-138.
58. Lee CM, Tannock IF. The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors. BMC Cancer. 2010;10:255.
59. Saggar JK, Fung AS, Patel KJ, et al. Use of molecular biomarkers to quantify the spatial distribution of effects of anticancer drugs in solid tumors. Mol Cancer Ther. 2013;12:542-552.
60. Tannock IF. Tumor physiology and drug resistance. Cancer Metastasis Rev. 2001;20:123-132.
61. Kim JJ, Tannock IF. Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer. 2005;5:516-525.
62. Saggar JK, Tannock IF. Chemotherapy rescues hypoxic tumor cells and induces their reoxygenation and repopulation-an effect that is inhibited by the hypoxia-activated pro-drug TH-302. Clin Cancer Res. 2015;21: 2107-2114.
63. Tahover E, Patil YP, Gabizon AA. Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index: focus on liposomes. Anticancer Drugs. 2015;26:241-258.
64. Vippola M, Falck GC, Lindberg HK, et al. Preparation of nanoparticle dispersions for in-vitro toxicity testing. Hum Exp Toxicol. 2009;28: 377-385.
65. Olive KP, JacobetzMA, Davidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mousemodel of pancreatic cancer. Science. 2009;324:1457-1461.
66. Provenzano PP, Cuevas C, Chang AE, et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;21:418-429.
67. Fan Y, DuW, He B, et al. The reduction of tumor interstitial fluid pressure by liposomal imatinib and its effect on combination therapy with liposomal doxorubicin. Biomaterials. 2013;34:2277-2288.
68. Yeo M, Kim DK, Kim YB, et al. Selective induction of apoptosis with proton pump inhibitor in gastric cancer cells. Clin Cancer Res. 2004;10: 8687-8696.
69. DeMilito A, Canese R,MarinoML, et al. pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. Int J Cancer. 2010;127:207-219.
70. Udelnow A, Kreyes A, Ellinger S, et al. Omeprazole inhibits proliferation and modulates autophagy in pancreatic cancer cells. PLoS One. 2011;6:e20143.
71. Saggar JK, Tannock IF. Activity of the hypoxia-activated pro-drug TH-302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy. Int J Cancer. 2014;134: 2726-2734.
72. Borad MJ, Reddy SG, Bahary N, et al. Randomized phase II trial of gemcitabine plus TH-302 versus gemcitabine in patients with advanced pancreatic cancer. J ClinOncol. 2015;33:1475-1481.
73. Davis AJ, Tannock JF. Repopulation of tumour cells between cycles of chemotherapy: a neglected factor. Lancet Oncol. 2000;1:86-93.
74. Wu L, Tannock IF. Selective estrogen receptor modulators as inhibitors of repopulation of human breast cancer cell lines after chemotherapy. Clin Cancer Res. 2003;9:4614-4618.